Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2023-09-28 | Reverse | 1:15 |
| 2017-08-28 | Reverse | 1:7 |
Synlogic, Inc. is a Cambridge-based clinical-stage biopharmaceutical company developing synthetic biotic medicines for metabolic, immunological, and cancer indications, with multiple drug candidates in Phase I and II trials.

Synlogic, a clinical-stage biotech developing oral Synthetic Biotics, halted its Phase 3 PKU trial, laid off 90% of staff, and is exploring strategic options, casting uncertainty on its future pipeline.
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
CING | $5.33 | COMPARE |
BCTX | $3.73 | COMPARE |
ALLR | $1.41 | COMPARE |
LEXX | $10.35 | COMPARE |
CUPR | $3.01 | COMPARE |
PCSA | $2.06 | COMPARE |
CRIS | $1.49 | COMPARE |